Emblem Competitors

Canopy Growth (TSE:WEED) and Emblem (CVE:EMC) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, profitability, institutional ownership and valuation.

Analyst Ratings

This is a summary of recent recommendations and price targets for Canopy Growth and Emblem, as provided by MarketBeat.com.

Canopy Growth currently has a consensus price target of C$38.46, indicating a potential upside of 18.49%. Given Canopy Growth's higher possible upside, analysts plainly believe Canopy Growth is more favorable than Emblem.

Profitability

This table compares Canopy Growth and Emblem's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Canopy Growth and Emblem's gross revenue, earnings per share (EPS) and valuation.

Emblem has lower revenue, but higher earnings than Canopy Growth. Emblem is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Leaf Mobile (TSE:LEAF) and Emblem (CVE:EMC) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Leaf Mobile and Emblem, as reported by MarketBeat.

Leaf Mobile currently has a consensus target price of C$0.75, indicating a potential upside of 111.27%. Given Leaf Mobile's higher probable upside, research analysts clearly believe Leaf Mobile is more favorable than Emblem.

Profitability

This table compares Leaf Mobile and Emblem's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Leaf Mobile and Emblem's top-line revenue, earnings per share (EPS) and valuation.

Leaf Mobile has higher revenue and earnings than Emblem. Leaf Mobile is trading at a lower price-to-earnings ratio than Emblem, indicating that it is currently the more affordable of the two stocks.

Summary

Leaf Mobile beats Emblem on 5 of the 7 factors compared between the two stocks.

OrganiGram (TSE:OGI) and Emblem (CVE:EMC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations for OrganiGram and Emblem, as reported by MarketBeat.

OrganiGram presently has a consensus price target of C$3.77, indicating a potential upside of 26.44%. Given OrganiGram's higher possible upside, research analysts clearly believe OrganiGram is more favorable than Emblem.

Profitability

This table compares OrganiGram and Emblem's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares OrganiGram and Emblem's top-line revenue, earnings per share (EPS) and valuation.

Emblem has lower revenue, but higher earnings than OrganiGram. Emblem is trading at a lower price-to-earnings ratio than OrganiGram, indicating that it is currently the more affordable of the two stocks.

Summary

OrganiGram beats Emblem on 4 of the 7 factors compared between the two stocks.

ICC Labs (CVE:ICC) and Emblem (CVE:EMC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Earnings & Valuation

This table compares ICC Labs and Emblem's top-line revenue, earnings per share (EPS) and valuation.

ICC Labs has higher earnings, but lower revenue than Emblem. Emblem is trading at a lower price-to-earnings ratio than ICC Labs, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ICC Labs and Emblem's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current ratings for ICC Labs and Emblem, as reported by MarketBeat.com.

Summary

ICC Labs beats Emblem on 4 of the 5 factors compared between the two stocks.

Emblem (CVE:EMC) and (CMED.TO) (TSE:CMED) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, profitability, valuation and risk.

Valuation and Earnings

This table compares Emblem and (CMED.TO)'s gross revenue, earnings per share and valuation.

(CMED.TO) has lower revenue, but higher earnings than Emblem.

Profitability

This table compares Emblem and (CMED.TO)'s net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Emblem and (CMED.TO), as provided by MarketBeat.

Summary

Emblem beats (CMED.TO) on 1 of the 1 factors compared between the two stocks.

Emblem (CVE:EMC) and (MJN.V) (CVE:MJN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, institutional ownership and valuation.

Analyst Recommendations

This is a summary of recent ratings and target prices for Emblem and (MJN.V), as reported by MarketBeat.

Valuation & Earnings

This table compares Emblem and (MJN.V)'s revenue, earnings per share and valuation.

(MJN.V) has lower revenue, but higher earnings than Emblem.

Dividends

Emblem pays an annual dividend of $0.46 per share and has a dividend yield of 24.5%. (MJN.V) pays an annual dividend of C$1.65 per share and has a dividend yield of 13.6%. Emblem pays out -242.1% of its earnings in the form of a dividend.

Profitability

This table compares Emblem and (MJN.V)'s net margins, return on equity and return on assets.

Summary

Emblem beats (MJN.V) on 3 of the 3 factors compared between the two stocks.